[Interferent RNA treatment: Example of primary hyperoxaluria]

Area of Science:

• Biochemistry
• Genetics
• Nephrology

Background:

• Primary hyperoxalurias are rare, inherited disorders leading to kidney failure and systemic complications.
• Type 1, the most common form, stems from a deficiency in liver peroxisomal alanine-glyoxylate aminotransferase, causing excessive oxalate production.
• Current treatments, including combined organ transplantation, have significant risks.

Purpose of the Study:

• To introduce novel interfering RNA (RNAi) therapies for primary hyperoxalurias.
• To evaluate the efficacy and safety of RNAi treatments in normalizing oxaluria.
• To explore the potential of RNAi to prevent kidney failure and obviate the need for transplantation.

Main Methods:

• RNA interference (RNAi) therapies targeting enzymes upstream of the primary metabolic defect.
• Administration of RNAi drugs via injection every 1 to 3 months.
• Monitoring of oxaluria levels and assessment of treatment tolerance.

Main Results:

• RNAi treatments successfully normalized oxaluria by blocking enzymatic synthesis (glycolate oxidase or lactate dehydrogenase A).
• The novel therapies demonstrated good patient tolerance.
• Early treatment is expected to prevent kidney failure, while late-stage treatment may avoid liver transplantation.

Conclusions:

• Interfering RNA treatments represent a promising new therapeutic strategy for primary hyperoxalurias.
• These treatments offer a potential alternative to combined liver and kidney transplantation.
• Early diagnosis and intervention with RNAi therapies can significantly improve patient outcomes.